デフォルト表紙
市場調査レポート
商品コード
1002739

抗肥満薬市場調査レポート-2026年までの予測-COVID-19の累積的影響

Anti-Obesity Drugs Market Research Report, by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 191 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.25円
抗肥満薬市場調査レポート-2026年までの予測-COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 191 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗肥満薬の市場規模は、2020年の31億7,357万米ドルから2025年末までに42億1,356万米ドルに拡大すると予測されています。

COVID-19は、未曾有の世界的な公衆衛生上の緊急事態であり、あらゆる業界に影響を及ぼしてきました。この長期的影響は、予測期間中に業界の成長に影響を与えると予測されています。私たちが進めている調査では、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げています。当レポートは、消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19について洞察を提供しています。アップデートされた調査では、COVID-19が市場に及ぼす影響を考慮し、洞察、分析、予測などを提供しています。

当レポートでは、抗肥満薬市場について調査し、市場の概要とともに、地域別の動向、COVID-19の累積的影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションと範囲
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画作成
    • 実行:調査実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • タイプ別見通し
  • 地域別見通し
  • 競合他社別見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 南北アメリカの抗肥満薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第7章 アジア太平洋地域の抗肥満薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第8章 欧州、中東・アフリカの抗肥満薬市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第9章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 契約、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第10章 企業のユーザビリティプロファイル

  • Alizyme
  • Arena Pharmaceuticals Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Norgine BV
  • Novo Nordisk AS
  • Orexigen Therapeutics
  • Pfizer Inc.
  • Rhythm Pharmaceuticals
  • Shionogi USA
  • Takeda Pharmaceuticals
  • Vivus Inc.
  • Zafgan
  • Zydus Cadila

第11章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET: MARKET DYNAMICS
  • FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 5. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 6. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 7. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 8. ARGENTINA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 9. BRAZIL ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 10. CANADA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 11. MEXICO ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 13. CALIFORNIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 14. FLORIDA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 15. ILLINOIS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 16. NEW YORK ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 17. OHIO ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 18. PENNSYLVANIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 19. TEXAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 21. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 23. CHINA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 24. INDIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 25. INDONESIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 26. JAPAN ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 27. MALAYSIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 28. PHILIPPINES ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 29. SOUTH KOREA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 30. THAILAND ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 31. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 32. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 34. FRANCE ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 35. GERMANY ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 36. ITALY ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 37. NETHERLANDS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 38. QATAR ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 39. RUSSIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 40. SAUDI ARABIA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 41. SOUTH AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 42. SPAIN ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. UNITED ARAB EMIRATES ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. UNITED KINGDOM ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. GLOBAL ANTI-OBESITY DRUGS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 46. GLOBAL ANTI-OBESITY DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 47. GLOBAL ANTI-OBESITY DRUGS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 48. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTI-OBESITY DRUGS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANTI-OBESITY DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET: SCORES
  • TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET: BUSINESS STRATEGY
  • TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET: PRODUCT SATISFACTION
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET: RANKING
  • TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 13. GLOBAL ANTI-OBESITY DRUGS MARKET: MERGER & ACQUISITION
  • TABLE 14. GLOBAL ANTI-OBESITY DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 15. GLOBAL ANTI-OBESITY DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 16. GLOBAL ANTI-OBESITY DRUGS MARKET: INVESTMENT & FUNDING
  • TABLE 17. GLOBAL ANTI-OBESITY DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 18. GLOBAL ANTI-OBESITY DRUGS MARKET: LICENSE & PRICING
  • TABLE 19. GLOBAL ANTI-OBESITY DRUGS MARKET: CONTACT DETAILS
目次
Product Code: MRR-434CCDA05192

The Global Anti-Obesity Drugs Market size was estimated at USD 3,173.57 Million in 2020 and expected to reach USD 3,374.55 Million in 2021, at a Compound Annual Growth Rate (CAGR) 6.67% to reach USD 4,675.53 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Anti-Obesity Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Geography, the Anti-Obesity Drugs Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-Obesity Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-Obesity Drugs Market, including Alizyme, Arena Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, Eisai Co. Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Orexigen Therapeutics, Pfizer Inc., Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceuticals, Vivus Inc., Zafgan, and Zydus Cadila.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Anti-Obesity Drugs Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-Obesity Drugs Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-Obesity Drugs Market?
  • 4. What is the competitive strategic window for opportunities in the Global Anti-Obesity Drugs Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Anti-Obesity Drugs Market?
  • 6. What is the market share of the leading vendors in the Global Anti-Obesity Drugs Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Anti-Obesity Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Geography Outlook
  • 3.4. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising burden of obesity and related chronic diseases
      • 5.1.1.2. Adoption of sedentary lifestyles
      • 5.1.1.3. Rising consumption of unhealthy fast-foods and ready meals
    • 5.1.2. Restraints
      • 5.1.2.1. Side-effects associated with drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing inclination towards health & fitness
      • 5.1.3.2. Rising awareness among people with collaborative strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatment options in market
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Americas Anti-Obesity Drugs Market

  • 6.1. Introduction
  • 6.2. Argentina
  • 6.3. Brazil
  • 6.4. Canada
  • 6.5. Mexico
  • 6.6. United States
    • 6.6.1. California
    • 6.6.2. Florida
    • 6.6.3. Illinois
    • 6.6.4. New York
    • 6.6.5. Ohio
    • 6.6.6. Pennsylvania
    • 6.6.7. Texas

7. Asia-Pacific Anti-Obesity Drugs Market

  • 7.1. Introduction
  • 7.2. China
  • 7.3. India
  • 7.4. Indonesia
  • 7.5. Japan
  • 7.6. Malaysia
  • 7.7. Philippines
  • 7.8. South Korea
  • 7.9. Thailand

8. Europe, Middle East & Africa Anti-Obesity Drugs Market

  • 8.1. Introduction
  • 8.2. France
  • 8.3. Germany
  • 8.4. Italy
  • 8.5. Netherlands
  • 8.6. Qatar
  • 8.7. Russia
  • 8.8. Saudi Arabia
  • 8.9. South Africa
  • 8.10. Spain
  • 8.11. United Arab Emirates
  • 8.12. United Kingdom

9. Competitive Landscape

  • 9.1. FPNV Positioning Matrix
    • 9.1.1. Quadrants
    • 9.1.2. Business Strategy
    • 9.1.3. Product Satisfaction
  • 9.2. Market Ranking Analysis
  • 9.3. Market Share Analysis, By Quadrant
  • 9.4. Market Share Analysis, By Company
  • 9.5. Competitive Scenario
    • 9.5.1. Merger & Acquisition
    • 9.5.2. Agreement, Collaboration, & Partnership
    • 9.5.3. New Product Launch & Enhancement
    • 9.5.4. Investment & Funding
    • 9.5.5. Award, Recognition, & Expansion

10. Company Usability Profiles

  • 10.1. Alizyme
  • 10.2. Arena Pharmaceuticals Inc.
  • 10.3. Bayer AG
  • 10.4. Boehringer Ingelheim GmbH
  • 10.5. Bristol-Myers Squibb
  • 10.6. Currax Pharmaceuticals LLC
  • 10.7. Eisai Co. Ltd
  • 10.8. F. Hoffmann-La Roche AG
  • 10.9. GlaxoSmithKline PLC
  • 10.10. Merck & Co. Inc.
  • 10.11. Norgine BV
  • 10.12. Novo Nordisk AS
  • 10.13. Orexigen Therapeutics
  • 10.14. Pfizer Inc.
  • 10.15. Rhythm Pharmaceuticals
  • 10.16. Shionogi USA
  • 10.17. Takeda Pharmaceuticals
  • 10.18. Vivus Inc.
  • 10.19. Zafgan
  • 10.20. Zydus Cadila

11. Appendix

  • 11.1. Discussion Guide
  • 11.2. License & Pricing
  • 11.3. Contact Details